An Update on Manipulation of Intestinal Microbiota in Halting Avoiding Progression of NAFLD to NASH thus Halting Cirrhosis and HCC Development
Kulvinder Kochar Kaur*
Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.
May 31, 2022; Published: June 27, 2022
It has been appreciated that what our dietary habits are, besides the diet constituent’s are parallel with the manner it is consumed, that has a robust impact on brain health. Over the last 2 decades comprehensive work has been performed for acquisition of insight regarding the key importance of trillions of bacteria that exist in the gastrointestinal tract (GIT) besides the bidirectional crosstalk amongst the heterogenous composition of this large microorganism community as well as opportunity of generation of various diseases like obesity, type 2 diabetes mellitus (T2DM), pain, neurodevelopmental, neurodegenerative as well as neuropsychiatric diseases .
- Kulvinder Kochar Kaur., et al. “The association of dietary fatty acids and gut microbiota alterations in the development of neuropsychiatric diseases: A systematic review”. Obesity Research - Open Journal1 (2020): 19-45.
- Kulvinder Kochar Kaur., et al. “An update on the Association of Gut - Liver Axis with Gut Microbiome Dysbiosis Correlated NAFLD along with NAFLD - HCC with Potential Therapeutic Approaches: a systematic review”. 2022 - under review Gastroenterology and Hepatology, Lngdom publishers.
- Song Q and Zhang X. “The role of gut - liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC”. Biomedicine 10 (2022): 524.
- Zhou D., et al. “Total faecal microbiota transplantation alleviates highfat diet induced non alcoholic steatohepatitis in mice via beneficial regulation of gut microbiota”. Scientific Report 7 (2017): 1-11.
- Kulvinder Kochar Kaur., et al. “An update on management of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepapititis-Is the time ripe for achieving resolution of NAFLD and NASH soon”. Journal of Endocrinology Research 2 (2021): 44-60.
- Kulvinder Kochar Kaur., et al. “The Association of Non Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity and Metabolic Syndrome –Etiopathogenetic Correlation along with Utilization for Diagnostic and Therapeutic Purposes-A Systematic review”. Journal of Endocrinology Research 2 (2021): 10-34.
- Xiang H., et al. “The role of intestinal microbiota in non alcoholic steatohepatitis”. Frontiers in Endocrinology (Lausanne) 13 (2022): 8126010.
- Kulvinder Kochar Kaur., et al. “Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review”. Advances in Obesity, Weight Management and Control 1 (2019): 21-28.
- Kulvinder Kochar Kaur., et al. “Will Probiotics Provide the Answer for Therapy of Non-alcoholic Fatty Liver Disease (NAFLD)? - A Systematic Review”. Biochemistry and Physiology 9 (2020): 257.
- Cani PD., et al. “Changes in gut microbiota control inflammation in Obese mice through a Mechanism involving GLP2 driven improvement in Gut permeability”. Gut 58 (2009): 1091-103.
- Kobyliac N., et al. “A multi strain Probiotic reduces the fatty liver index, cytokines and amino transferase levels: evidence from a randomized Clinical trial”. Journal of Gastrointestinal and Liver Diseases 27 (2018): 41-49.
- Ferolla SM., et al. “Beneficial effects of symbiotic supplementation on hepatic steatosis and anthropometric parameters but not on Gut permeability in a population of non alcoholic steatohepapititis”. Nutrients 8 (2016): 397.
- Kulvinder Kochar Kaur. “Delivered a talk on 30th September on ’Advantages and Limitations of utilizing Clostridium species as Probiotics - A Systematic Review”. in a webinar held by Gastroenterology conference on 30th September (2020).